Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Treatment with Solriamfetol in Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea Syndrome (OSA) with a 12-week Treatment Period

NCT06103825 is registered in ClinicalTrials.gov with Ignis Therapeutics (Suzhou) Limited as lead sponsor.

NCT NCT06103825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06103825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Treatment with Solriamfetol in Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea Syndrome (OSA) with a 12-week Treatment Period
Lead sponsor
Ignis Therapeutics (Suzhou) Limited
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2023
Completion date
August 19, 2024
Enrollment
204 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

excessive daytime sleepiness, sleep apnea, obstructive